Home › Lung Cancer › New Hampshire
Lung Cancer clinical trials in New Hampshire
12 studies for Lung Cancer are looking for participants at sites in New Hampshire.
Cities in New Hampshire
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- New Hampshire Oncology Hematology PA-Concord, Concord
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
- Solinsky Center for Cancer Care, Manchester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04267848Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
- The Dana-Farber Cancer Institute at Londonderry, Londonderry
RecruitingPhase 3
Ages 70 and older · All sexes · Updated Sep 30, 2026 · NCT06096844Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Dartmouth-Hitchcock Medical Center, Lebanon
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06881784A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Local Institution - 0467, Lebanon
- Local Institution - 0600, Manchester
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07063745A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Dartmouth-Hitchcock Medical Center, Lebanon
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05624996Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT05642572Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
- Solinsky Center for Cancer Care, Manchester
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated May 5, 2026 · NCT06616584Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
RecruitingPhase 2
18 Minutes · All sexes · Updated May 5, 2026 · NCT06031688A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
- Dartmouth Hitchcock Medical Center, Lebanon
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT05948865Healthy Homes Study
- Dartmouth Cancer Center, Lebanon
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Jan 30, 2026 · NCT05833334From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.